A statistical modelling approach for determining the cause of reported respiratory syndromes from internet-based participatory surveillance when influenza virus and SARS-CoV-2 are co-circulating.

Publication date: Dec 01, 2024

Symptom-only case definitions are insufficient to discriminate COVID-like illness from acute respiratory infection (ARI) or influenza-like illness (ILI), due to the overlap in case definitions. Our objective was to develop a statistical method that does not rely on case definitions to determine the contribution of influenza virus and SARS-CoV-2 to the ARI burden during periods when both viruses are circulating. Data sources used for testing the approach were weekly ARI syndrome reports from the Infectieradar participatory syndromic surveillance system during the analysis period (the first 25 weeks of 2022, in which SARS-CoV-2 and influenza virus co-circulated in the Netherlands) and data from virologically tested ARI (including ILI) patients who consulted a general practitioner in the same period. Estimation of the proportions of ARI attributable to influenza virus, SARS-CoV-2, or another cause was framed as an inference problem, through which all data sources are combined within a Bayesian framework to infer the weekly numbers of ARI reports attributable to each cause. Posterior distributions for the attribution proportions were obtained using Markov Chain Monte-Carlo methods. Application of the approach to the example data sources indicated that, of the total ARI reports (total of 11,312; weekly mean of 452) during the analysis period, the model attributed 35. 4% (95% CrI: 29. 2-40. 0%) and 27. 0% (95% CrI: 19. 3-35. 2%) to influenza virus and SARS-CoV-2, respectively. The proposed statistical model allows the attribution of respiratory syndrome reports from participatory surveillance to either influenza virus or SARS-CoV-2 infection in periods when both viruses are circulating, but comparability of the participatory surveillance and virologically tested populations is important. Portability for use by other countries with established participatory respiratory surveillance systems is an asset.

Open Access PDF

Concepts Keywords
Influenza Ari
Internet Circulating
Netherlands Co
Cov
Definitions
Illness
Influenza
Participatory
Period
Respiratory
Sars
Statistical
Surveillance
Virus
Weekly

Semantics

Type Source Name
disease MESH syndromes
disease MESH influenza
disease IDO symptom
disease MESH infection
disease MESH Data sources
disease MESH SARS-CoV-2 infection
pathway REACTOME SARS-CoV-2 Infection
pathway REACTOME Reproduction
disease MESH infectious diseases
disease MESH causes
disease MESH virus infection
disease MESH community spread
disease IDO facility
disease IDO pathogen
disease MESH sore throat
disease MESH rhinitis
disease MESH parainfluenza
disease MESH allergies
drug DRUGBANK Aspartame
drug DRUGBANK Ranitidine
disease MESH uncertainty
disease IDO susceptibility
pathway REACTOME Influenza Infection
drug DRUGBANK Pentaerythritol tetranitrate
disease MESH respiratory infections
drug DRUGBANK Coenzyme M

Original Article

(Visited 1 times, 1 visits today)